References
- Mehra, S., J. Walker, K. Patterson, and M. J. Fritzler. 2013. Autoantibodies in systemic sclerosis. Autoimmun. Rev. 12: 340–354
- Steen, V. D. 2005. Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum. 35: 35–42
- Castelino, F. V., and J. Varga. 2013. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Exp. Rev. Clin. Immunol. 9: 1077–1090
- Wolfe, F. A. E., and G. Sharp. 1977. Antinuclear antibody with distinct specificity for polymyositis. J. Clin. Investigat. 59: 176–178
- Iaccarino, L., M. Gatto, S. Bettio, et al. 2013. Overlap connective tissue disease syndromes. Autoimmun. Rev. 12: 363–373
- Mahler, M., and R. Raijmakers. 2007. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6: 432–437
- Koschik R. W. II, N. Fertig, M. R. Lucas, et al. 2012. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin. Exp. Rheumatol. 30(2 Suppl 71): S12–S16
- Hanke, K., C. S. Bruckner, C. Dahnrich, et al. 2009. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res. Ther. 11: R22
- Villalta, D., T. Imbastaro, S. Di Giovanni, et al. 2012. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun. Rev. 12: 114–120
- Alhajeri, H., M. Hudson, M. Fritzler, et al. 2015. 2013 American College of Rheumatology/European league against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. ACR (Hoboken). 67: 582–587
- Nikpour, M., P. Hissaria, J. Byron, et al. 2011. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res. Ther. 13: R211
- Steele, R., M. Hudson, E. Lo, et al. 2012. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res. 64: 519–524
- Hsu, V. M., A. E. Moreyra, A. C. Wilson, et al. 2008. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J. Rheumatol. 35: 458–465
- Mierau, R., P. Moinzadeh, G. Riemekasten, et al. 2011. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res. Ther. 13: R172
- Marguerie, C., C. C. Bunn, J. Copier, et al. 1992. The clinical and immunological features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine 71: 327–336
- Oddis, C. V., Y. Okana, W. A. Rudert, et al. 1992. Serum autoantibody to the nucleolar antigen PM-Scl. Arthritis Rheum. 35: 1211–1217
- D’Aoust, J., M. Hudson, S. Tatibouet, et al. 2014. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol. 66: 1608–1615
- Muro, Y., Y. Hosono, K. Sugiura, et al. 2015. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res. Ther. 17: 57